Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11][12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...

4 days ago · About ENHERTU ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, ENHERTU is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform.

3 days ago · AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug Administration (FDA ...

2 days ago · Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

4 days ago · AstraZeneca and Daiichi Sankyo’s ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug ...

May 3, 2024 · On August 5, the agency gave an accelerated approval for trastuzumab deruxtecan —often called T-DXd—to treat anyone with any advanced solid cancer if their tumors produce high levels of the protein HER2, or HER2-positive.

Learn more about ENHERTU® (fam-trastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.

Sep 14, 2024 · Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy.

Jul 5, 2022 · Trastuzumab deruxtecan, also known as T-DXd, “is the first HER2- targeted therapy shown to provide clinically meaningful improvement in progression-free and overall survival compared with standard chemotherapy in people with HER2-low metastatic breast cancer,” Dr. Modi said at the meeting.

Dec 11, 2020 · deruxtecan is a toxic substance that kills cells when they attempt to divide and grow. It becomes active once the trastuzumab component has attached to HER2 and enters the cancer cell. Deruxtecan blocks an enzyme called topoisomerase I which is involved in copying cell DNA needed to make new cells.